Helen Bhatt

Helen Bhatt studies the clinical significance of eosinophilia during cancer immunotherapy, demonstrating that blood eosinophil increases during checkpoint inhibitor treatment correlate with improved response rates and survival in melanoma and NSCLC patients. Her research has revealed that eosinophil expansion during IO is driven by IL-5 and IL-33 and reflects activation of type 2 immune pathways that complement T cell anti-tumor immunity. She has contributed to understanding eosinophils as predictive biomarkers for immunotherapy response. Her translational work connects eosinophil biology with clinical immunotherapy outcomes.